Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection

被引:49
|
作者
Yönem, A
Çakir, B
Güler, S
Azal, Ö
Çorakçi, A
机构
[1] Gulhane Sch Med, Dept Endocrinol, Ankara, Turkey
[2] Ankara Educ & Res Hosp, Dept Endocrinol & Metab, Ankara, Turkey
来源
DIABETES OBESITY & METABOLISM | 2001年 / 3卷 / 05期
关键词
granulocyte-colony stimulating factor; diabetes mellitus; diabetic foot infection; respiratory burst; phagocytosis; polymorphonuclear leucocytes;
D O I
10.1046/j.1463-1326.2001.00142.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Foot infections and the subsequent amputation of a lower extremity are the most common cause of hospitalization among patients with diabetes mellitus. Although there are several reasons for susceptibility to infection in diabetic patients, white blood cell dysfunction is considered to be an important cause for this tendency. Granulocyte-colony stimulating factor (G-CSF) increases the release of neutrophils from the bone marrow and improves neutrophil functions. Based on this knowledge, the aim of the present study was to investigate the effects of addition of G-CSF to the treatment of foot infections in diabetic patients. Methods: Thirty diabetic patients with foot infection were included in the study. Fifteen of the patients received standard treatment consisting of local wound care and antibiotics (standard goup), and the other 15 patients received G-CSF besides standard treatment (G-CSF group). The objectives of this study were to determine the time to resolution of infection, time to hospital discharge, need for surgical intervention, and the effects of G-CSF on phagocytosis and respiratory burst of neutrophils. Results: Treatment with G-CSF led to significantly higher neutrophil counts on the 5th and loth days, and at the end of treatment in the G-CSF treated group compared to the standard group. Respiratory burst of neutrophils increased significantly in both the G-CSF group (from 1.6 +/-0.3 to 2.3 +/-0.5. p=0.001) and the standard group (from 2.0 +/-0.4 to 2.3 +/-0.4, p=0.02) with treatment. But, while phagocytosis of neutrophils increased significantly in the G-CSF group (from 70.4 +/-2.0 to 74.5 +/-1.9, p=0.004), it did not change significantly in the standard group (from 68.1 +/-0.2 to 69.4 +/-1.9, p=0.3) with treatment. Duration of hospitalization (26.9 +/-2.0 vs. 28.3 days, p<0.05), duration of parenteral antibiotic administration (22.9<plus/minus>2.0 vs. 23.3 +/-1.9 days, p<0.05), time to resolution of infection (23.6<plus/minus>1.8 vs. 22.3 +/-1.7 days, p<0.05), and need for amputation (13.3% vs. 20%, p>0.05) were similar between the G-CSF and the standard groups. Conclusions: Although G-CSF improves neutrophil function as well as increasing the absolute numbers, this improvement is not associated with shortening of duration of antibiotic administration, duration of hospital stay or need for amputation in diabetic foot infection.
引用
收藏
页码:332 / 337
页数:6
相关论文
共 50 条
  • [1] New treatment with granulocyte-colony stimulating factor in diabetic foot ulceration
    Kreyden, OP
    Hafner, J
    Burg, G
    Nestle, FO
    HAUTARZT, 2001, 52 (04): : 327 - 330
  • [2] Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection
    Gough, A
    Clapperton, M
    Rolando, N
    Foster, AVM
    PhilpottHoward, J
    Edmonds, ME
    LANCET, 1997, 350 (9081): : 855 - 859
  • [3] Granulocyte-colony stimulating factor as a treatment for diabetic neuropathy in rat
    Kim, Kyung-Soo
    Song, Yi-Sun
    Jin, Jiyong
    Joe, Jun-Ho
    So, Byung-Im
    Park, Jun-Young
    Fang, Cheng-Hu
    Kim, Mi Jung
    Cho, Youl-Hee
    Hwang, Sejin
    Ro, Young-Suck
    Kim, Hyuck
    Ahn, You-Hem
    Sung, Hak-Joon
    Sung, Jung-Joon
    Park, Sung-Hye
    Lipton, Stuart A.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2015, 414 (0C) : 64 - 72
  • [4] Granulocyte-colony-stimulating factor in diabetic foot infection
    Chantelau, E
    Kimmerle, R
    LANCET, 1998, 351 (9099): : 370 - 370
  • [5] Evaluation of granulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers
    T. Kästenbauer
    B. Hörnlein
    G. Sokol
    K. Irsigler
    Diabetologia, 2003, 46 : 27 - 30
  • [6] Evaluation of granulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers
    Kästenbauer, T
    Hörnlein, B
    Sokol, G
    Irsigler, K
    DIABETOLOGIA, 2003, 46 (01) : 27 - 30
  • [7] Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections
    Cruciani, M.
    Lipsky, B. A.
    Mengoli, C.
    de Lalla, F.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (03):
  • [8] Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections
    Cruciani, Mario
    Lipsky, Benjamin A.
    Mengoli, Carlo
    de Lalla, Fausto
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (08):
  • [9] Granulocyte-colony stimulating factor in the treatment of colchicine poisoning
    Critchley, JAJH
    Critchley, LAH
    Yeung, EA
    Young, RP
    Young, RJ
    Chan, TYK
    Goh, VKM
    HUMAN & EXPERIMENTAL TOXICOLOGY, 1997, 16 (04): : 229 - 232
  • [10] Neonatal neutropenia, nosocomial infection and granulocyte-colony stimulating factor
    Escande, B
    Kuhn, P
    Gaugler, C
    Messer, J
    ARCHIVES DE PEDIATRIE, 2003, 10 (02): : 93 - 95